...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons >Pre-Transplant IFN-gamma ELISPOTs Are Associated with Post-Transplant Renal Function in African American Renal Transplant Recipients.
【24h】

Pre-Transplant IFN-gamma ELISPOTs Are Associated with Post-Transplant Renal Function in African American Renal Transplant Recipients.

机译：在非裔美国人肾脏移植接受者中，移植前的IFN-γELISPOT与移植后的肾功能有关。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Final crossmatch testing is routinely used to assess the risk of antibody-mediated graft injury/rejection post-transplant. Analogously, we postulated that quantitative measurements of anti-donor effector/memory T cells pre-transplant would independently assess post-transplant risk. To address this hypothesis, we determined the frequencies of pre-transplant, donor-specific interferon-gamma (IFN-gamma) enzyme-linked immunosorbent spots (ELISPOTs) and correlated the results with post-transplant outcomes in 37 African American recipients of deceased donor kidney transplants treated with tacrolimus- and sirolimus-based immunosuppression. A positive ELISPOT test (>25 spots/300 000 cells) was detected in 14 (38%) of 37 patients. The incidence of biopsy-proven acute rejection was 50% (7/14) in ELISPOT-positive versus 17% (4/23) in ELISPOT-negative patients (p = 0.036). Calculated glomerular filtration rate (MDRD) at 12 months was 37 +/- 16 mL/min in ELISPOT-positive versus 55 +/- 20 mL/min in ELISPOT-negative patients (p = 0.01). ELISPOT status remained a correlate of allograft function at 12 months by linear regression analysis (p = 0.001), independent of rejection and other contributing variables. Pre-transplant donor-directed IFN-gamma ELISPOT assessment of anti-donor cellular immunity may function as a 'cellular crossmatch' and independently correlates with renal allograft function in African Americans receiving tacrolimus- and sirolimus-based immunosuppression.
机译：最终交叉匹配测试通常用于评估移植后抗体介导的移植物损伤/排斥的风险。类似地，我们假设移植前抗供体效应子/记忆T细胞的定量测量将独立评估移植后的风险。为了解决这个假设，我们确定了37位非裔美国捐赠者的移植前，供体特异性干扰素-γ（IFN-γ）酶联免疫吸附斑点（ELISPOTs）的频率，并将结果与​​移植后结果相关联基于他克莫司和西罗莫司的免疫抑制治疗的肾脏移植。在37例患者中，有14例（38％）检测到阳性ELISPOT测试（> 25个点/ 300 000个细胞）。经活检证实的急性排斥反应在ELISPOT阳性患者中为50％（7/14），在ELISPOT阴性患者中为17％（4/23）（p = 0.036）。 ELISPOT阳性患者在12个月时的肾小球滤过率（MDRD）为37 +/- 16 mL / min，而ELISPOT阴性患者为55 +/- 20 mL / min（p = 0.01）。通过线性回归分析，ELISPOT状态在12个月时仍与同种异体移植功能相关（p = 0.001），与排斥反应和其他影响因素无关。在接受基于他克莫司和西罗莫司的免疫抑制的非裔美国人中，针对抗供体细胞免疫的移植前供体指导的IFN-γELISPOT评估可能起到“细胞交叉匹配”的作用，并与肾脏同种异体移植功能独立相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号